1. Healthy female subjects of non-childbearing potential and male subjects, who at the
time of screening are between ages of 18 and 55 years inclusive. Healthy is defined as
no clinically relevant abnormalities identified by a detailed medical history, full
physical examination, including blood pressure and pulse rate measurement, 12-lead
electrocardiogram, or clinical laboratory tests.
2. Body mass index of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).
3. Subjects who are willing and able to comply with all scheduled visits, treatment plan,
laboratory tests, and other study procedures.
1. Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or
allergic disease (including drug allergies, but excluding untreated, asymptomatic,
seasonal allergies at the time of dosing).
2. Treatment with an investigational drug within 30 days (or as determined by the local
requirement) or 5 half-lives preceding the first dose of investigational product
(whichever is longer).
3. Screening supine BP greater than or equal to 140 mm Hg (systolic) or greater than or
equal to 90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is
greater than or equal to 140 mm Hg (systolic) or greater than or equal to 90 mm Hg
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP values
should be used to determine the subject's eligibility.
4. Screening supine 12-lead ECG demonstrating a corrected QT (QTc) interval >450 msec or
a QRS interval >120 msec. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG
should be repeated 2 more times and the average of the 3 QTc or QRS values should be
used to determine the subject's eligibility.
5. Subjects with ANY of the following abnormalities in clinical laboratory tests at
screening, as assessed by the study-specific laboratory and confirmed by a single
repeat test, if deemed necessary:
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level greater
than or equal to 1.5x upper limit of normal (ULN);
- Total bilirubin level greater than or equal to 1.5x ULN; subjects with a history
of Gilbert's syndrome may have direct bilirubin measured and would be eligible
for this study provided the direct bilirubin level is less than or equal to ULN.
6. Use of prescription or nonprescription drugs and dietary supplements within 7 days or
5 half-lives (whichever is longer) prior to the first dose of investigational product.
7. Unwilling or unable to comply with the criteria in the Lifestyle Requirements section
of this protocol.
8. Other acute or chronic medical or psychiatric conditions